Details of the Drug

General Information of Drug (ID: DM0C9IL)

Drug Name
Ranolazine
Synonyms
RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination
Indication
Disease Entry ICD 11 Status REF
Chronic/stable angina BA40.1 Approved [1], [2], [3]
Paroxysmal atrial fibrillation BC81.30 Phase 2 [4]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 427.5
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 64% [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.5 mL/min/kg [7]
Elimination
An estimated 5% of an ingested dose is excreted as unchanged drug [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [9]
Metabolism
The drug is metabolized via the liver [10]
Unbound Fraction
The unbound fraction of drug in plasma is 0.38% [7]
Vd
The volume of distribution (Vd) of drug is 53.2 L [11]
Chemical Identifiers
Formula
C24H33N3O4
IUPAC Name
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
Canonical SMILES
CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
InChI
InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)
InChIKey
XKLMZUWKNUAPSZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
56959
ChEBI ID
CHEBI:87690
CAS Number
95635-55-5
DrugBank ID
DB00243
TTD ID
D03HYQ
VARIDT ID
DR00246
INTEDE ID
DR1394
ACDINA ID
D00584

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasminogen (PLG) TTP86E2 PLMN_HUMAN Modulator [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic/stable angina
ICD Disease Classification BA40.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Plasminogen (PLG) DTT PLG 8.61E-01 -0.01 -0.09
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ranolazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Ranolazine and Bepridil. Angina pectoris [BA40] [48]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Ranolazine and Dronedarone. Angina pectoris [BA40] [48]
Nifedipine DMSVOZT Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Nifedipine. Angina pectoris [BA40] [49]
Coadministration of a Drug Treating the Disease Different from Ranolazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Moderate Decreased metabolism of Ranolazine caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [50]
Sarecycline DMLZNIQ Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [49]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Ranolazine and Ivosidenib. Acute myeloid leukaemia [2A60] [51]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Midostaurin. Acute myeloid leukaemia [2A60] [52]
Idarubicin DMM0XGL Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [53]
Daunorubicin DMQUSBT Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [53]
Arn-509 DMT81LZ Major Increased metabolism of Ranolazine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [49]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [54]
Oliceridine DM6MDCF Major Decreased metabolism of Ranolazine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [55]
Mitotane DMU1GX0 Major Increased metabolism of Ranolazine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [49]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [52]
Tripelennamine DMZBU15 Minor Decreased metabolism of Ranolazine caused by Tripelennamine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [49]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Tacrine. Alzheimer disease [8A20] [48]
Galantamine DMEO794 Moderate Decreased metabolism of Ranolazine caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [49]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Rivastigmine. Alzheimer disease [8A20] [48]
Donepezil DMIYG7Z Minor Decreased metabolism of Ranolazine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [56]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Ranolazine and Metronidazole. Amoebiasis [1A36] [57]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Ranolazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [58]
Methylphenobarbital DMDSWAG Major Increased metabolism of Ranolazine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [59]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [52]
Clobazam - Lundbeck DMW1OQ0 Minor Decreased metabolism of Ranolazine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [49]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Promazine. Appearance/behaviour symptom [MB23] [52]
Voriconazole DMAOL2S Major Decreased metabolism of Ranolazine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [57]
Posaconazole DMUL5EW Major Decreased metabolism of Ranolazine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [57]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Levalbuterol. Asthma [CA23] [60]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Terbutaline. Asthma [CA23] [61]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Pirbuterol. Asthma [CA23] [61]
Budesonide DMJIBAW Moderate Decreased metabolism of Ranolazine caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [62]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Salbutamol. Asthma [CA23] [60]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Formoterol. Asthma [CA23] [61]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Ranolazine caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [63]
Atomoxetine DM5L6HI Moderate Decreased metabolism of Ranolazine caused by Atomoxetine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [64]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [54]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Desipramine. Attention deficit hyperactivity disorder [6A05] [52]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [52]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [52]
Dalfopristin DM4LTKV Major Decreased metabolism of Ranolazine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [52]
Clarithromycin DM4M1SG Major Decreased metabolism of Ranolazine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Ranolazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [48]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Ranolazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [65]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [52]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [52]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [52]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [52]
Telithromycin DMZ4P3A Major Decreased metabolism of Ranolazine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Retigabine. Behcet disease [4A62] [52]
Cariprazine DMJYDVK Moderate Decreased metabolism of Ranolazine caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [54]
Erdafitinib DMI782S Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [66]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Loperamide. Bowel habit change [ME05] [67]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Eribulin. Breast cancer [2C60-2C6Y] [48]
Talazoparib DM1KS78 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [54]
Lapatinib DM3BH1Y Major Decreased metabolism of Ranolazine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
LY2835219 DM93VBZ Moderate Decreased metabolism of Ranolazine caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [68]
Tucatinib DMBESUA Major Decreased metabolism of Ranolazine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Palbociclib DMD7L94 Moderate Decreased metabolism of Ranolazine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Alpelisib DMEXMYK Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [49]
Tamoxifen DMLB0EZ Major Decreased metabolism of Ranolazine caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [69]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Ranolazine caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Ranolazine and Toremifene. Breast cancer [2C60-2C6Y] [48]
Bosutinib DMTI8YE Moderate Decreased metabolism of Ranolazine caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Ranolazine and Grepafloxacin. Bronchitis [CA20] [65]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Ranolazine and Sotalol. Cardiac arrhythmia [BC9Z] [48]
Atorvastatin DMF28YC Major Decreased metabolism of Ranolazine caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [54]
Macitentan DMP79A1 Moderate Decreased metabolism of Ranolazine caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [71]
Secobarbital DM14RF5 Major Increased metabolism of Ranolazine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [49]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [61]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [60]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [61]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [61]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [61]
Phenylbutazone DMAYL0T Major Increased metabolism of Ranolazine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [49]
Fidaxomicin DMFP6MV Minor Decreased clearance of Ranolazine due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [57]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Ranolazine caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [48]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Oxaliplatin. Colorectal cancer [2B91] [52]
Intedanib DMSTA36 Moderate Decreased metabolism of Ranolazine caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [72]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Isoproterenol. Conduction disorder [BC63] [60]
Ulipristal DMBNI20 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [49]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Halothane. Corneal disease [9A76-9A78] [52]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Propofol. Corneal disease [9A76-9A78] [73]
Ropivacaine DMSPJG2 Minor Decreased metabolism of Ranolazine caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [74]
Alfentanil DMVO0UB Moderate Decreased metabolism of Ranolazine caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [75]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Probucol. Coronary atherosclerosis [BA80] [52]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Ranolazine and Methadone. Cough [MD12] [48]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Ranolazine caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [57]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Clofazimine. Crohn disease [DD70] [76]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Ranolazine and Pasireotide. Cushing syndrome [5A70] [48]
Aminoglutethimide DMWFHMZ Major Increased metabolism of Ranolazine caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [49]
Lumacaftor DMCLWDJ Major Increased metabolism of Ranolazine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [59]
Ivacaftor DMZC1HS Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [49]
MK-8228 DMOB58Q Major Decreased metabolism of Ranolazine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [49]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [77]
Aprepitant DM053KT Major Decreased metabolism of Ranolazine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [49]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Sertraline. Depression [6A70-6A7Z] [52]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Trimipramine. Depression [6A70-6A7Z] [52]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Imipramine. Depression [6A70-6A7Z] [52]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Fluoxetine. Depression [6A70-6A7Z] [52]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Nortriptyline. Depression [6A70-6A7Z] [52]
Nefazodone DM4ZS8M Major Decreased metabolism of Ranolazine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [57]
Paroxetine DM5PVQE Moderate Decreased metabolism of Ranolazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [49]
Duloxetine DM9BI7M Moderate Decreased metabolism of Ranolazine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [78]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Ranolazine and Escitalopram. Depression [6A70-6A7Z] [48]
OPC-34712 DMHG57U Major Decreased metabolism of Ranolazine caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [79]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Clomipramine. Depression [6A70-6A7Z] [52]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Trazodone. Depression [6A70-6A7Z] [80]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Amitriptyline. Depression [6A70-6A7Z] [52]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Amoxapine. Depression [6A70-6A7Z] [52]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Mirtazapine. Depression [6A70-6A7Z] [81]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Protriptyline. Depression [6A70-6A7Z] [52]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Doxepin. Depression [6A70-6A7Z] [52]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Maprotiline. Depression [6A70-6A7Z] [52]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Venlafaxine. Depression [6A70-6A7Z] [52]
Griseofulvin DMK54YG Major Increased metabolism of Ranolazine caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [49]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Ranolazine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [82]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [52]
Fenfluramine DM0762O Moderate Decreased metabolism of Ranolazine caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Primidone DM0WX6I Major Increased metabolism of Ranolazine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Felbamate DM1V5ZS Major Increased metabolism of Ranolazine caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Oxcarbazepine DM5PU6O Major Increased metabolism of Ranolazine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Cenobamate DMGOVHA Major Increased metabolism of Ranolazine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ranolazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Fosphenytoin DMOX3LB Major Increased metabolism of Ranolazine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Phenobarbital DMXZOCG Major Increased metabolism of Ranolazine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Diphenhydramine DMKQTBA Moderate Decreased metabolism of Ranolazine caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [49]
Timolol DM3NXRU Moderate Decreased metabolism of Ranolazine caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [49]
Nicardipine DMCDYW7 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Nicardipine. Essential hypertension [BA00] [49]
Bay 80-6946 DMLOS5R Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [83]
Tazemetostat DMWP1BH Major Increased metabolism of Ranolazine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [49]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Solifenacin. Functional bladder disorder [GC50] [52]
Mirabegron DMS1GYT Minor Decreased metabolism of Ranolazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [49]
Tolterodine DMSHPW8 Minor Decreased metabolism of Ranolazine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [84]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Ranolazine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [85]
Itraconazole DMCR1MV Major Decreased metabolism of Ranolazine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [57]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Pentamidine. Fungal infection [1F29-1F2F] [52]
Terbinafine DMI6HUW Minor Decreased metabolism of Ranolazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [49]
Clotrimazole DMMFCIH Major Decreased metabolism of Ranolazine caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [49]
Miconazole DMPMYE8 Moderate Decreased metabolism of Ranolazine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [86]
Ketoconazole DMPZI3Q Major Decreased metabolism of Ranolazine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [57]
Cimetidine DMH61ZB Minor Decreased metabolism of Ranolazine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [49]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Ranolazine and Cisapride. Gastro-oesophageal reflux disease [DA22] [48]
Ripretinib DM958QB Moderate Decreased metabolism of Ranolazine caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [57]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [52]
Avapritinib DMK2GZX Moderate Decreased metabolism of Ranolazine caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [54]
Sulfinpyrazone DMEV954 Major Increased metabolism of Ranolazine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [49]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Ranolazine caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [87]
Spironolactone DM2AQ5N Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Spironolactone. Heart failure [BD10-BD1Z] [49]
Carvedilol DMHTEAO Moderate Decreased metabolism of Ranolazine caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [49]
Boceprevir DMBSHMF Major Decreased metabolism of Ranolazine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
Telaprevir DMMRV29 Major Decreased metabolism of Ranolazine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
GS-5885 DMSL3DX Moderate Decreased clearance of Ranolazine due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [49]
Rifampin DMA8J1G Major Increased metabolism of Ranolazine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [59]
Rifapentine DMCHV4I Major Increased metabolism of Ranolazine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [49]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [88]
MK-1439 DM215WE Minor Decreased metabolism of Ranolazine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Delavirdine DM3NF5G Major Decreased metabolism of Ranolazine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Ranolazine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [52]
Cobicistat DM6L4H2 Major Decreased metabolism of Ranolazine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Efavirenz DMC0GSJ Major Increased metabolism of Ranolazine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Saquinavir DMG814N Major Decreased metabolism of Ranolazine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Etravirine DMGV8QU Major Increased metabolism of Ranolazine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [52]
Amprenavir DMLMXE0 Major Decreased metabolism of Ranolazine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Darunavir DMN3GCH Major Decreased metabolism of Ranolazine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Atazanavir DMSYRBX Major Decreased metabolism of Ranolazine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Maraviroc DMTL94F Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [90]
Simvastatin DM30SGU Major Decreased metabolism of Ranolazine caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [54]
BMS-201038 DMQTAGO Moderate Decreased clearance of Ranolazine due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [91]
Cerivastatin DMXCM7H Moderate Decreased metabolism of Ranolazine caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [92]
Cinacalcet DMCX0K3 Minor Decreased metabolism of Ranolazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [49]
Aliskiren DM1BV7W Moderate Decreased metabolism of Ranolazine caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [48]
Nebivolol DM7F1PA Moderate Decreased metabolism of Ranolazine caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [49]
Verapamil DMA7PEW Major Decreased metabolism of Ranolazine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [49]
Diltiazem DMAI7ZV Major Decreased metabolism of Ranolazine caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [49]
Pindolol DMD2NV7 Moderate Decreased metabolism of Ranolazine caused by Pindolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [49]
Metoprolol DMOJ0V6 Moderate Decreased metabolism of Ranolazine caused by Metoprolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [49]
Felodipine DMOSW35 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Felodipine. Hypertension [BA00-BA04] [49]
Conivaptan DM1V329 Major Decreased metabolism of Ranolazine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [49]
Tolvaptan DMIWFRL Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [93]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Ranolazine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [54]
Givosiran DM5PFIJ Minor Decreased metabolism of Ranolazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [49]
Berotralstat DMWA2DZ Major Decreased clearance of Ranolazine due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [94]
Suvorexant DM0E6S3 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [49]
Amobarbital DM0GQ8N Major Increased metabolism of Ranolazine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [49]
Pentobarbital DMFNH7L Major Increased metabolism of Ranolazine caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [49]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Ranolazine caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [95]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [54]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Phenolphthalein. Irritable bowel syndrome [DD91] [48]
Naloxegol DML0B41 Minor Decreased metabolism of Ranolazine caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [96]
Pemigatinib DM819JF Moderate Decreased metabolism of Ranolazine caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [54]
Glycerol phenylbutyrate DMDGRQO Minor Decreased metabolism of Ranolazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [49]
Crizotinib DM4F29C Major Decreased metabolism of Ranolazine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [49]
Brigatinib DM7W94S Moderate Decreased metabolism of Ranolazine caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [57]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Ranolazine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [97]
PF-06463922 DMKM7EW Major Increased metabolism of Ranolazine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [49]
Dacomitinib DMOH8VY Minor Decreased metabolism of Ranolazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [49]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Ranolazine and Osimertinib. Lung cancer [2C25] [98]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Ranolazine caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [99]
Capmatinib DMYCXKL Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Ranolazine and Selpercatinib. Lung cancer [2C25] [54]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Ranolazine and Lumefantrine. Malaria [1F40-1F45] [57]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Ranolazine and Halofantrine. Malaria [1F40-1F45] [100]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Ranolazine and Chloroquine. Malaria [1F40-1F45] [101]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Ranolazine and Hydroxychloroquine. Malaria [1F40-1F45] [101]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Quinine. Malaria [1F40-1F45] [52]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Primaquine. Malaria [1F40-1F45] [52]
Mefloquine DMWT905 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Mefloquine. Malaria [1F40-1F45] [52]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [52]
Idelalisib DM602WT Major Decreased metabolism of Ranolazine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [57]
GDC-0199 DMH0QKA Major Decreased clearance of Ranolazine due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [57]
IPI-145 DMWA24P Major Decreased metabolism of Ranolazine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [49]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Ranolazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [102]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Ranolazine caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [103]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Ranolazine caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [104]
Vincristine DMINOX3 Moderate Decreased metabolism of Ranolazine caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [105]
Ponatinib DMYGJQO Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [49]
Arry-162 DM1P6FR Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Arry-162. Melanoma [2C30] [57]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Ranolazine and Vemurafenib. Melanoma [2C30] [48]
Selumetinib DMC7W6R Moderate Decreased metabolism of Ranolazine caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [106]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and LGX818. Melanoma [2C30] [107]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Ranolazine caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [48]
Methysergide DM1EF73 Moderate Decreased metabolism of Ranolazine caused by Methysergide mediated inhibition of CYP450 enzyme. Migraine [8A80] [50]
Dihydroergotamine DM5IKUF Moderate Decreased metabolism of Ranolazine caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [87]
Ubrogepant DM749I3 Moderate Decreased metabolism of Ranolazine caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [108]
Propranolol DM79NTF Moderate Decreased metabolism of Ranolazine caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [49]
Rimegepant DMHOAUG Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Rimegepant. Migraine [8A80] [109]
Lasmiditan DMXLVDT Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Lasmiditan. Migraine [8A80] [110]
Midazolam DMXOELT Moderate Decreased metabolism of Ranolazine caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [105]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Ranolazine and Panobinostat. Multiple myeloma [2A83] [111]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Thalidomide. Multiple myeloma [2A83] [57]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Ranolazine and Siponimod. Multiple sclerosis [8A40] [57]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Ranolazine and Fingolimod. Multiple sclerosis [8A40] [48]
Ozanimod DMT6AM2 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Ozanimod. Multiple sclerosis [8A40] [52]
Rifabutin DM1YBHK Major Increased metabolism of Ranolazine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [49]
Bexarotene DMOBIKY Major Increased metabolism of Ranolazine caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [49]
Fedratinib DM4ZBK6 Major Decreased metabolism of Ranolazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [49]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Ranolazine and Nilotinib. Myeloproliferative neoplasm [2A20] [48]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Ranolazine caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Imatinib DM7RJXL Major Decreased metabolism of Ranolazine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [49]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Dasatinib. Myeloproliferative neoplasm [2A20] [52]
Modafinil DMYILBE Major Increased metabolism of Ranolazine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [49]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Ranolazine and Droperidol. Nausea/vomiting [MD90] [48]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Prochlorperazine. Nausea/vomiting [MD90] [52]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Promethazine. Nausea/vomiting [MD90] [52]
Rolapitant DM8XP26 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [112]
Cyclizine DM9G7BS Minor Decreased metabolism of Ranolazine caused by Cyclizine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [49]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Palonosetron. Nausea/vomiting [MD90] [52]
Netupitant DMEKAYI Major Decreased metabolism of Ranolazine caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [52]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Granisetron. Nausea/vomiting [MD90] [52]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Ranolazine and Dolasetron. Nausea/vomiting [MD90] [48]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Ondansetron. Nausea/vomiting [MD90] [52]
Bupropion DM5PCS7 Minor Decreased metabolism of Ranolazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [49]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Entrectinib. Non-small cell lung cancer [2C25] [57]
Lorcaserin DMG6OYJ Minor Decreased metabolism of Ranolazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [49]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Ranolazine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [49]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Ranolazine and Levomethadyl Acetate. Opioid use disorder [6C43] [54]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Lofexidine. Opioid use disorder [6C43] [48]
S-297995 DM26IH8 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [54]
Olaparib DM8QB1D Moderate Decreased metabolism of Ranolazine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [113]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Rucaparib. Ovarian cancer [2C73] [52]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Ranolazine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [49]
Codeine DMJX6ZG Moderate Decreased metabolism of Ranolazine caused by Codeine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [114]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Ranolazine caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [49]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Buprenorphine. Pain [MG30-MG3Z] [48]
Oxycodone DMXLKHV Major Decreased metabolism of Ranolazine caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [57]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Triclabendazole. Parasitic worm infestation [1F90] [52]
Istradefylline DM20VSK Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [49]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Pimavanserin. Parkinsonism [8A00] [115]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Apomorphine. Parkinsonism [8A00] [52]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Famotidine. Peptic ulcer [DA61] [57]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ranolazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [116]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Ranolazine and Lefamulin. Pneumonia [CA40] [117]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Ranolazine caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [50]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Ranolazine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [57]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Ritodrine. Preterm labour/delivery [JB00] [61]
Progesterone DMUY35B Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Progesterone. Preterm labour/delivery [JB00] [49]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Degarelix. Prostate cancer [2C82] [54]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Ranolazine and ABIRATERONE. Prostate cancer [2C82] [54]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Nilutamide. Prostate cancer [2C82] [54]
Enzalutamide DMGL19D Major Increased metabolism of Ranolazine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [49]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Flutamide. Prostate cancer [2C82] [54]
Relugolix DMK7IWL Major Decreased clearance of Ranolazine due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [118]
Darolutamide DMV7YFT Minor Decreased metabolism of Ranolazine caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [119]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Ranolazine caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [120]
Silodosin DMJSBT6 Moderate Decreased metabolism of Ranolazine caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [121]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Alfuzosin. Prostate hyperplasia [GA90] [52]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Levomepromazine. Psychotic disorder [6A20-6A25] [52]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Fluphenazine. Psychotic disorder [6A20-6A25] [52]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Triflupromazine. Psychotic disorder [6A20-6A25] [52]
Bosentan DMIOGBU Major Increased metabolism of Ranolazine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [49]
Riociguat DMXBLMP Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [57]
Everolimus DM8X2EH Moderate Decreased metabolism of Ranolazine caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [122]
Axitinib DMGVH6N Moderate Decreased metabolism of Ranolazine caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [54]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Sorafenib. Renal cell carcinoma [2C90] [48]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Ranolazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [123]
Celecoxib DM6LOQU Minor Decreased metabolism of Ranolazine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [49]
Dexamethasone DMMWZET Major Increased metabolism of Ranolazine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [49]
Nafcillin DMN9RPO Major Increased metabolism of Ranolazine caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [49]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Ranolazine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [49]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Ranolazine and Mesoridazine. Schizophrenia [6A20] [48]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Ranolazine and Thioridazine. Schizophrenia [6A20] [48]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Ranolazine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [124]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Ranolazine and Iloperidone. Schizophrenia [6A20] [48]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Paliperidone. Schizophrenia [6A20] [52]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Ranolazine and Haloperidol. Schizophrenia [6A20] [48]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Perphenazine. Schizophrenia [6A20] [52]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Chlorpromazine. Schizophrenia [6A20] [52]
Clozapine DMFC71L Moderate Decreased metabolism of Ranolazine caused by Clozapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [49]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Trifluoperazine. Schizophrenia [6A20] [52]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Ranolazine and Ziprasidone. Schizophrenia [6A20] [48]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Risperidone. Schizophrenia [6A20] [52]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Olanzapine. Schizophrenia [6A20] [57]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Ranolazine and Amisulpride. Schizophrenia [6A20] [125]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Asenapine. Schizophrenia [6A20] [48]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Ranolazine and Pimozide. Schizophrenia [6A20] [54]
Fentanyl DM8WAHT Moderate Decreased metabolism of Ranolazine caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [105]
Sufentanil DMU7YEL Moderate Decreased metabolism of Ranolazine caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [105]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Vardenafil. Sexual dysfunction [HA00-HA01] [52]
Voxelotor DMCS6M5 Major Decreased metabolism of Ranolazine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [49]
LDE225 DMM9F25 Moderate Decreased metabolism of Ranolazine caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [126]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ranolazine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [54]
Gefitinib DM15F0X Minor Decreased metabolism of Ranolazine caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Cyclophosphamide DM4O2Z7 Minor Decreased metabolism of Ranolazine caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Vinblastine DM5TVS3 Moderate Decreased metabolism of Ranolazine caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [105]
Docetaxel DMDI269 Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [127]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Ranolazine caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Armodafinil DMGB035 Major Increased metabolism of Ranolazine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Ranolazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [48]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [52]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [54]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [52]
Vinorelbine DMVXFYE Moderate Decreased metabolism of Ranolazine caused by Vinorelbine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [105]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Ranolazine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [54]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [52]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Ranolazine and Ibutilide. Supraventricular tachyarrhythmia [BC81] [48]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Ranolazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [48]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Ranolazine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [128]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [129]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Ranolazine and Anagrelide. Thrombocytosis [3B63] [48]
Apixaban DM89JLN Moderate Decreased metabolism of Ranolazine caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [54]
Brilinta DMBR01X Moderate Decreased clearance of Ranolazine due to the transporter inhibition by Brilinta. Thrombosis [DB61-GB90] [49]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Lenvatinib. Thyroid cancer [2D10] [52]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Ranolazine and Papaverine. Tonus and reflex abnormality [MB47] [130]
Sirolimus DMGW1ID Moderate Decreased metabolism of Ranolazine caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [105]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Ranolazine caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [105]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Astemizole. Vasomotor/allergic rhinitis [CA08] [52]
Chlorpheniramine DM5URA2 Moderate Decreased metabolism of Ranolazine caused by Chlorpheniramine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [49]
Clemastine DMBZWQL Minor Decreased metabolism of Ranolazine caused by Clemastine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [49]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [52]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Ranolazine and Disopyramide. Ventricular tachyarrhythmia [BC71] [48]
Mexiletine DMCTE9R Moderate Decreased metabolism of Ranolazine caused by Mexiletine mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [49]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Ranolazine and Procainamide. Ventricular tachyarrhythmia [BC71] [48]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Propafenone. Ventricular tachyarrhythmia [BC71] [52]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Ranolazine and Flecainide. Ventricular tachyarrhythmia [BC71] [52]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Ranolazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [48]
⏷ Show the Full List of 354 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ranolazine 500 mg tablet 500 mg 12 HR Extended Release Oral Tablet Oral
Ranolazine 1000 mg tablet 1000 mg 12 HR Extended Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7291).
2 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
3 Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006 Jul;92 Suppl 4:iv1-iv5.
4 Clinical pipeline report, company report or official report of Gilead.
5 BDDCS applied to over 900 drugs
6 Singulair (montelukast sodium) US FDA Label 2019
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Rayner-Hartley E, Sedlak T: Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.
9 Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006 May 23;113(20):2462-72. doi: 10.1161/CIRCULATIONAHA.105.597500.
10 Battershill PE, Clissold SP: Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989 Nov;38(5):658-702. doi: 10.2165/00003495-198938050-00002.
11 Australian Assessment Report
12 Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
13 Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9.
14 Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
25 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
26 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
27 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
28 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
29 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
30 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
31 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
32 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
33 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
34 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
35 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
36 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
37 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
38 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
39 The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
40 Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
41 Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
42 Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
43 Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
44 Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
45 Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
46 Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
47 Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
48 Canadian Pharmacists Association.
49 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
50 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
51 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
52 European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine.".
53 Multum Information Services, Inc. Expert Review Panel.
54 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
56 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
57 Cerner Multum, Inc. "Australian Product Information.".
58 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
59 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
60 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
61 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
62 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
63 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
64 Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
65 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
66 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
67 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
68 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
69 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
70 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
71 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
72 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
73 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
74 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
75 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
76 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
77 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
78 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
79 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
80 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
81 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
82 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
83 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
84 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
85 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
87 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
88 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
89 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
90 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
92 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
93 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
94 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
95 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
96 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
97 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
98 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
99 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
100 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
101 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
102 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
103 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
104 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
105 Pierce DA, Reeves-Daniel AM "Ranolazine-tacrolimus interaction." Ann Pharmacother 44 (2010): 1844-9. [PMID: 20876828]
106 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
107 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
108 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
109 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
110 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
111 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
112 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
113 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
114 Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
115 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
116 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
117 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
118 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
119 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
120 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
121 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
122 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
123 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
124 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
125 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
126 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
127 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
128 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
129 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
130 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]